Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ Medivation AD drug fails trial

Pfizer and Medivation's Alzheimer's Disease treatment, Dimebon (latrepirdin), has failed to meet its efficacy endpoints in a phase III trial

Pfizer and Medivation's Alzheimer's Disease (AD) treatment, Dimebon (latrepirdin), has failed to meet its co-primary or secondary efficacy endpoints in a phase III trial.

The phase III, multi-national, double-blind, placebo-controlled ,CONNECTION trial, involved 598 patients with mild-to-moderate AD.

Dr David Hung, president and CEO of Medivation, said: "The results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer's community." 

He went on to say that Medivation would be working with Pfizer to analyse the data from the trial. 

Dr Briggs W Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer said: "We recognise the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease."

Both the CONNECTION study and a separate phase III study found Dimebon to be well tolerated when dosed alone or in combination with other approved AD therapies.

Dimebon is being studied in four other ongoing randomised, double-blind, placebo-controlled phase III studies, which currently are enrolling. 

Medivation and Pfizer have a global collaboration to develop and commercialise Dimebon for the treatment of Alzheimer's disease and Huntington's disease. Under the terms of the agreement, the companies work together on the Dimebon development programme.

4th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics